ClinicalTrials.gg
RecruitingNCT03106701Updated Oct 2, 2023

Epicardial Ablation in Brugada Syndrome. An Extension Study of 500 BrS.Patients

An interventional study of Ablation in ECG Brugada Pattern, sponsored by IRCCS Policlinico S. Donato. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-10-02.

Sponsored by IRCCS Policlinico S. Donato · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2023, 3 years 1 month ago, but the record still lists the study as recruiting.
  • Started Mar 2017; still recruiting 9 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Brugada Syndrome with a site in Italy — 5 open to participants now, 5 under way, none of them phase 3. Brugada Syndrome · Italy.

Started
2017
with 1 other
No phase
5 of 12
3 open now
Registered
4th of 12
by date
Lead sponsor
5 of 12
IRCCS Policlinico S. Donato

Among the 12 studies in Brugada Syndrome with a site in Italy, this one is one of 2 that started in 2017, is one of 5 with no phase, and was the 4th registered.

Brugada Syndrome

53 studies on the registry are indexed under Brugada Syndrome; 19 are open to participants now.

Browse Brugada Syndrome studies →

Open to participants now

5 of the 12 studies in Brugada Syndrome with a site in Italy are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 15 Brugada Syndrome studies recruiting now, 10 (67%) set no upper age limit and none (0%) stop at 75 or younger; 6 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Brugada Syndrome with a site in Italy, or all of them as a file.
02

Study summary

This study represents an extension of a previous study (NCT02641431) on the acute and long-term benefit of epicardial ablation on elimination of both BrS-ECG pattern and VT/VF inducibility in 500 consecutive BrS patients.

Read the detailed description

According to previous protocol (NCT02641431), 300 additional consecutive selected patients having an ICD implantation will be enrolled up to a total of 500 BrS patients. Echocardiography with cardiac deformation analysis, three-dimensional color-coded voltage, activation and duration electroanatomical maps before and after ajmaline (1mg/kg in 5 minutes) wiil determine the site and the size of the arrhythmogenic substrate as characterized by abnormally prolonged fragmented ventricular potentials and potential wall motion abnormalities. Primary endpoint will be identification and elimination of this electrophysiological substrate by RF applications leading to ECG pattern normalization and VT/VF non-inducibility before and after ajmaline. Patients will be followed up to 10 years after ablation by sequential 12-lead ECG and Holter recording, Echocardiography, ICD interrogation, VT/VF inducibility patterns before and after ajmaline test.

03

Conditions studied

  • ECG Brugada Pattern

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Symptomatic BrS patients with typical BrS-related symptoms (cardiac arrest or syncope) or without typical BrS-related symptoms (dizziness, palpitations, presyncope, dyspnea) ICD implantation, spontaneous or ajmaline-induced type 1 Br pattern.

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years, prior epicardial ablation, pregnancy, co-morbidities.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Ablation

    Radiofrequency epicardial ablation

    Procedure: Ablation

Interventions

  • ProcedureAblation

    Epicardial Radiofrequency ablation

06

What researchers measure

Primary outcomes

  1. Type 1 BrS-ECG pattern elimination by epicardial ablation before and after ajmaline test.

    Normalization of ECG pattern after elimination by radio-frequency ablation of all abnormal epicardial potentials

    Time frame: 1 day after ablation

  2. VT/VF inducibility

    Programmed stimulation was achieved at twice the diastolic threshold and randomly performed at RV apex and RV outflow tract using up to 3 drive cycle lengths (from 600 to 350ms) and up to three extrastimuli (S2-S4) delivered from the apex and outflow tract of the right ventricle.

    Time frame: immediately after mapping and ablation

  3. Absence of VT/VF

    Absence of VT/VF by ICD interrogation

    Time frame: 1,3,6,12,18,24,36,48,60,72,84,96,108,120 months after ablation

Secondary outcomes

  1. Absence of Br Pattern and RV mechanical abnormalities using echo and cardiac deformation analysis before and after ajmaline test

    Abolition of typical BrS-ECG pattern and RV mechanical abnormalities before and after ajmaline.

    Time frame: 3 months

  2. Absence of VA episodes at EP study

    Non-inducibility of VT/VT at programmed electrophysiological study

    Time frame: 3 months

  3. Absence of Br Pattern at ajmaline test

    Normalization of 12-lead ECG recording and echo parameters at baseline and after ajmaline test

    Time frame: 6 months

  4. Absence of VA episodes

    ICD interrogation

    Time frame: 6 months

  5. Absence of VA episodes

    ICD interrogation and ajmaline test

    Time frame: 12 months

  6. Absence of Br Pattern at ajmaline test

    Normalization of 12-lead ECG recording and echo parameters at baseline and after ajmaline test

    Time frame: 12 months

  7. Absence of Br Pattern at ajmaline test

    Normalization of 12-lead ECG recording at baseline and after ajmaline test

    Time frame: 18 months

  8. Absence of VA episodes

    ICD interrogation

    Time frame: 24 months

  9. Absence of Br ECG pattern after ajmaline test

    Normalization of 12-lead ECG recording at baseline and after ajmaline test

    Time frame: 24 months

  10. Absence of VA episodes at EP study

    ICD interrogation

    Time frame: 36 months

  11. Absence of Br Pattern at ajmaline test

    Normalization of 12-lead ECG recording at baseline and after ajmaline test

    Time frame: 36 months

  12. Absence of Br Pattern at ajmaline test

    Normalization of 12-lead ECG recording at baseline and after ajmaline test

    Time frame: 48 months

  13. Absence of VA episodes at EP study

    ICD interrogation

    Time frame: 48 months up to 120 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Ciconte G, Santinelli V, Vicedomini G, Borrelli V, Monasky MM, Micaglio E, Giannelli L, Negro G, Giordano F, Mecarocci V, Mazza BC, Locati E, Anastasia L, Calovic Z, Pappone C. Non-invasive assessment of the arrhythmogenic substrate in Brugada syndrome using signal-averaged electrocardiogram: clinical implications from a prospective clinical trial. Europace. 2019 Dec 1;21(12):1900-1910. doi: 10.1093/europace/euz295. PubMed 31647530 ↗
  • Ciconte G, Santinelli V, Brugada J, Vicedomini G, Conti M, Monasky MM, Borrelli V, Castracane W, Aloisio T, Giannelli L, Di Dedda U, Pozzi P, Ranucci M, Pappone C. General Anesthesia Attenuates Brugada Syndrome Phenotype Expression: Clinical Implications From a Prospective Clinical Trial. JACC Clin Electrophysiol. 2018 Apr;4(4):518-530. doi: 10.1016/j.jacep.2017.11.013. Epub 2018 Feb 13. PubMed 30067493 ↗
  • Pappone C, Ciconte G, Manguso F, Vicedomini G, Mecarocci V, Conti M, Giannelli L, Pozzi P, Borrelli V, Menicanti L, Calovic Z, Della Ratta G, Brugada J, Santinelli V. Assessing the Malignant Ventricular Arrhythmic Substrate in Patients With Brugada Syndrome. J Am Coll Cardiol. 2018 Apr 17;71(15):1631-1646. doi: 10.1016/j.jacc.2018.02.022. PubMed 29650119 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2017 (actual). Primary completion is estimated for Sep 2023, 78 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2017
First posted
Apr 10, 2017
StartActual
Mar 14, 2017
Primary completionEst.
Sep 28, 2023
CompletionEst.
Dec 30, 2023
Last update
Oct 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03106701
Responsible party
Carlo Pappone (Department Director, MD, IRCCS Policlinico S. Donato) — Principal investigator
First posted
Apr 10, 2017
Start date
Mar 14, 2017
Primary completion
Sep 28, 2023 (estimated)
Completion
Dec 30, 2023 (estimated)
Last update
Oct 2, 2023

Study contacts

Carlo Pappone, MD
Contact
carlo.pappone@af-ablation.org
+39 02 52774260
Carlo Pappone, MD
principal investigator · IRCCS Policlinico San Donato, Milan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion